APT Pharmaceuticals Secures $32 Million in Series B Financing

APT Pharmaceuticals, a specialty drug development company focused on inhaled treatments for serious lung diseases, announced today the completion of a $32.3 million Series B financing.

Comments

• Find It

• Recently Written

  • test post
  • Possible Case: Stem Cell Therapy Web Sites
  • (Revised December 3, 2008) Health Canada Warns Consumers That The Unauthorized Natural Health Product Kwan Loong Medicated Oil May Cause Adverse Health Effects
  • Possible Case: Innohep (Tinzaparin
  • Brand-Name Drugs Do Not Appear Superior to Generic Drugs for Treating Cardiovascular Disease
  • PhRMA Statement on JAMA Study
  • Innohep (tinzaparin sodium injection)
  • Tracking Eye Disorders in Statin Users; Predicting Visual Outcomes…
  • Epilepsy Drug May Increase Risk of Autism in Children
  • Paladin Labs, GSK Sign Dexedrine Pact

• Categories

  • News

• Monthly Archives

  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • December 1969

• Blogroll

  • Attorney Daily » Drug Injury News
  • Dangerous Drug Lawyer
  • Drugs.com - Pharma News
  • FDA MedWatch
  • Health Canada RSS
  • Lawyers and Settlements :: Drugs/Medical
  • Medication News

• Admin

  • Register
  • Log in
  • XHTML

Copyright © 2008 Drug Injury News